Non-profit generics company Civica has entered into a co-development and commercial agreement with Indian biopharmaceutical manufacturer GeneSys Biologics, which will allow it to manufacture and distribute insulins for the US at significantly lower prices than those currently on the market.
Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Initiative Will Produce Biosimilars Of Lantus, Humalog And Novolog
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
